Sathgen Therapeutics announces completion of first cohort in phase 1 clinical trial with anti-cancer…
Sathgen aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate…
Recover your password.
A password will be e-mailed to you.